abstract: The @entity2 ( @entity2 ) family is reportedly overexpressed in @entity1 , and @entity4 kinase inhibitors (TKIs) have been suggested as treatment. @entity10 ( @entity10  ) is a selective inhibitor of the @entity2 and @entity12 is a dual inhibitor of both the @entity2 and @entity9 ( @entity0 @entity2 type  2 receptor). Both compounds compete with the binding of @entity5 to the @entity4 kinase domain of the respective receptors to inhibit receptor autophosphorylation causing suppression of signal transduction. Unfortunately, resistance to these inhibitors is a major clinical issue. The purpose of the present study was to use protein array analysis to compare the signaling pathway(s) induced by @entity10 and @entity12 , in UM-UC-5 (drug-sensitive) and UM-UC-14 (drug-resistant) @entity1 cells and to identify molecular markers that may be useful predictors of their efficacy. The results revealed that phosphorylation of @entity2 , @entity11 , Met and @entity8 was markedly overexpressed in the sensitive cell line (UM-UC-5) and was strongly inhibited by the TKIs. Other notable differences included decreased phosphorylation of RSK, GSK3, @entity13 , @entity3 and @entity7 by TKIs in the sensitive cells. In contrast, phosphorylated @entity6 was highly expressed in the resistant cell line (UM-UC-14) and TKIs had no effect in the resistant cells. Overall results suggest that phosphorylated @entity11 , @entity8 and @entity6 may be used as biomarkers to determine the sensitivity of @entity1 to TKIs. In particular, a combination of these markers may be more likely to predict the sensitivity to TKIs.

title: Biomarkers for predicting response to XXXX kinase inhibitors in drug-sensitive and drug-resistant @entity0 @entity1 cells.

answer: @entity4


abstract: The @entity2 ( @entity2 ) family is reportedly overexpressed in @entity1 , and @entity4 kinase inhibitors (TKIs) have been suggested as treatment. @entity10 ( @entity10  ) is a selective inhibitor of the @entity2 and @entity12 is a dual inhibitor of both the @entity2 and @entity9 ( @entity0 @entity2 type  2 receptor). Both compounds compete with the binding of @entity5 to the @entity4 kinase domain of the respective receptors to inhibit receptor autophosphorylation causing suppression of signal transduction. Unfortunately, resistance to these inhibitors is a major clinical issue. The purpose of the present study was to use protein array analysis to compare the signaling pathway(s) induced by @entity10 and @entity12 , in UM-UC-5 (drug-sensitive) and UM-UC-14 (drug-resistant) @entity1 cells and to identify molecular markers that may be useful predictors of their efficacy. The results revealed that phosphorylation of @entity2 , @entity11 , Met and @entity8 was markedly overexpressed in the sensitive cell line (UM-UC-5) and was strongly inhibited by the TKIs. Other notable differences included decreased phosphorylation of RSK, GSK3, @entity13 , @entity3 and @entity7 by TKIs in the sensitive cells. In contrast, phosphorylated @entity6 was highly expressed in the resistant cell line (UM-UC-14) and TKIs had no effect in the resistant cells. Overall results suggest that phosphorylated @entity11 , @entity8 and @entity6 may be used as biomarkers to determine the sensitivity of @entity1 to TKIs. In particular, a combination of these markers may be more likely to predict the sensitivity to TKIs.

title: Biomarkers for predicting response to @entity4 kinase inhibitors in drug-sensitive and drug-resistant @entity0 XXXX cells.

answer: @entity1


abstract: The @entity2 ( @entity2 ) family is reportedly overexpressed in @entity1 , and @entity4 kinase inhibitors (TKIs) have been suggested as treatment. @entity10 ( @entity10  ) is a selective inhibitor of the @entity2 and @entity12 is a dual inhibitor of both the @entity2 and @entity9 ( @entity0 @entity2 type  2 receptor). Both compounds compete with the binding of @entity5 to the @entity4 kinase domain of the respective receptors to inhibit receptor autophosphorylation causing suppression of signal transduction. Unfortunately, resistance to these inhibitors is a major clinical issue. The purpose of the present study was to use protein array analysis to compare the signaling pathway(s) induced by @entity10 and @entity12 , in UM-UC-5 (drug-sensitive) and UM-UC-14 (drug-resistant) @entity1 cells and to identify molecular markers that may be useful predictors of their efficacy. The results revealed that phosphorylation of @entity2 , @entity11 , Met and @entity8 was markedly overexpressed in the sensitive cell line (UM-UC-5) and was strongly inhibited by the TKIs. Other notable differences included decreased phosphorylation of RSK, GSK3, @entity13 , @entity3 and @entity7 by TKIs in the sensitive cells. In contrast, phosphorylated @entity6 was highly expressed in the resistant cell line (UM-UC-14) and TKIs had no effect in the resistant cells. Overall results suggest that phosphorylated @entity11 , @entity8 and @entity6 may be used as biomarkers to determine the sensitivity of @entity1 to TKIs. In particular, a combination of these markers may be more likely to predict the sensitivity to TKIs.

title: Biomarkers for predicting response to @entity4 kinase inhibitors in drug-sensitive and drug-resistant XXXX @entity1 cells.

answer: @entity0


abstract: OBJECTIVES: To study the temporal pattern of @entity2 ( @entity2 ) from onset of symptoms to the final diagnosis and to study the type and the frequency of the disease. METHODS: Retrospective analysis of the case record forms of the @entity0 attending the Genetic Clinic over a period of 12 y (January 2002- December 2013) was undertaken. Only the data of the @entity0 who had confirmatory enzyme analysis or mutation study for @entity2 was further analysed. The age at onset, suspicion of the illness, first clinical presentation to a tertiary Genetic centre, and the age at the final diagnosis of these confirmed cases was noted. RESULTS: A total of 5,858 @entity0 were referred to the Genetic clinic in this period. The diagnosis of @entity2 was suspected in 532 @entity0 (9.08  % of all referrals) and it could be confirmed in 119 cases (2.03  % of all referrals). Maximum @entity0 were diagnosed with @entity1 (31.93  %) followed by Mucopolysaccharidoses (20.16  %). Mutation analysis was available in 21 @entity0 (17.64  % of the diagnosed cases). The median time interval between onset and suspicion was 6  mo. The median interval between onset and presentation to the authors'  Genetic clinic was 12  mo. The median interval between the onset of the disease and its confirmation was 14  mo. The median interval between presentation to the Genetic centre and diagnosis was barely 1  mo. CONCLUSIONS: The incidence of @entity2 at authors' centre was 2.03  %, though it was suspected in 9.08  % of @entity0 . The delay in diagnosis was hugely due to the late suspicion and thereby the late referral to a tertiary centre.

title: The Face of XXXX in India: A Need for Early Diagnosis.

answer: @entity2


abstract: PURPOSE: To evaluate the potential benefit of 4   radiation therapy in recurrent, locally advanced, or metastatic @entity3 treated with stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Twenty-seven @entity1 with 29 @entity2 who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44  Gy (range, 35-44  Gy) in 5 fractions. Three @entity1 with @entity6 , metastatic @entity0 , and primary @entity5 received 35  Gy, 22.5  Gy, and 40  Gy in 5 fractions, respectively. Novel 4   treatment plans were created for each @entity1 to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late @entity4 , @entity2 ( @entity2 ), and normal tissue complication probability were determined. RESULTS: Using 4   plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4   plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10  Gy and 20  Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10  months (range, 1-41  months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean @entity2 of 42.2%, which increased to 45.9% with 4   plans. For 10-Gy and 20-Gy dose escalation, 4   plans increased @entity2 from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >= 3 late @entity4 was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4   planning at the prescribed and escalated doses. CONCLUSIONS: 4   plans may allow dose escalation with significant and consistent improvements in critical organ sparing, @entity2 control, and coverage.

title: 4   Noncoplanar Stereotactic Body Radiation Therapy for @entity3 : Potential to Improve Tumor Control and Late XXXX .

answer: @entity4


abstract: PURPOSE: To evaluate the potential benefit of 4   radiation therapy in recurrent, locally advanced, or metastatic @entity3 treated with stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Twenty-seven @entity1 with 29 @entity2 who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44  Gy (range, 35-44  Gy) in 5 fractions. Three @entity1 with @entity6 , metastatic @entity0 , and primary @entity5 received 35  Gy, 22.5  Gy, and 40  Gy in 5 fractions, respectively. Novel 4   treatment plans were created for each @entity1 to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late @entity4 , @entity2 ( @entity2 ), and normal tissue complication probability were determined. RESULTS: Using 4   plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4   plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10  Gy and 20  Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10  months (range, 1-41  months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean @entity2 of 42.2%, which increased to 45.9% with 4   plans. For 10-Gy and 20-Gy dose escalation, 4   plans increased @entity2 from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >= 3 late @entity4 was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4   planning at the prescribed and escalated doses. CONCLUSIONS: 4   plans may allow dose escalation with significant and consistent improvements in critical organ sparing, @entity2 control, and coverage.

title: 4   Noncoplanar Stereotactic Body Radiation Therapy for XXXX : Potential to Improve Tumor Control and Late @entity4 .

answer: @entity3


abstract: This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity7 , the first fully synthetic @entity6 ( @entity6 ) reductase inhibitor, in elderly @entity0 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity0 (mean age 68 +/- 5 years) with @entity2 [low density lipoprotein (LDL) @entity1 > 160 mg/dl] were enrolled in the trial. @entity7 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity1 , LDL @entity1 , high density lipoprotein (HDL) @entity1 , @entity5 , apolipoproteins B ( @entity4 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity1 , LDL @entity1 , @entity3 , HDL @entity1 , @entity4 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity7 significantly (p < 0.001, ANOVA test) reduced total @entity1 , LDL @entity1 and @entity4 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity1 , -21%; LDL @entity1 , -27%). The total @entity1 : HDL @entity1 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity0 showed a reduction > or = 20% for LDL @entity1 . @entity5 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of @entity7 , a new XXXX reductase inhibitor, in elderly hypercholesterolaemic @entity0 .

answer: @entity6


abstract: This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity7 , the first fully synthetic @entity6 ( @entity6 ) reductase inhibitor, in elderly @entity0 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity0 (mean age 68 +/- 5 years) with @entity2 [low density lipoprotein (LDL) @entity1 > 160 mg/dl] were enrolled in the trial. @entity7 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity1 , LDL @entity1 , high density lipoprotein (HDL) @entity1 , @entity5 , apolipoproteins B ( @entity4 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity1 , LDL @entity1 , @entity3 , HDL @entity1 , @entity4 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity7 significantly (p < 0.001, ANOVA test) reduced total @entity1 , LDL @entity1 and @entity4 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity1 , -21%; LDL @entity1 , -27%). The total @entity1 : HDL @entity1 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity0 showed a reduction > or = 20% for LDL @entity1 . @entity5 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of XXXX , a new @entity6 reductase inhibitor, in elderly hypercholesterolaemic @entity0 .

answer: @entity7


abstract: This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity7 , the first fully synthetic @entity6 ( @entity6 ) reductase inhibitor, in elderly @entity0 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity0 (mean age 68 +/- 5 years) with @entity2 [low density lipoprotein (LDL) @entity1 > 160 mg/dl] were enrolled in the trial. @entity7 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity1 , LDL @entity1 , high density lipoprotein (HDL) @entity1 , @entity5 , apolipoproteins B ( @entity4 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity1 , LDL @entity1 , @entity3 , HDL @entity1 , @entity4 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity7 significantly (p < 0.001, ANOVA test) reduced total @entity1 , LDL @entity1 and @entity4 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity1 , -21%; LDL @entity1 , -27%). The total @entity1 : HDL @entity1 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity0 showed a reduction > or = 20% for LDL @entity1 . @entity5 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of @entity7 , a new @entity6 reductase inhibitor, in elderly hypercholesterolaemic XXXX .

answer: @entity0


abstract: We assessed the left ventricular (LV) contractile reserve in young adults with repaired @entity1 and interrupted aortic arch by determination of LV force-frequency relation (FFR). Eighteen (7 @entity0 ) @entity0 aged 24.2    5.4  years and 20 (9 @entity0 ) healthy controls were studied. Blood pressures in the right arm were measured by oscillometry. Transmitral early (E) and late (A) diastolic velocities, tissue Doppler-derived mitral annular systolic (sm), early diastolic (em) and late diastolic (am) velocities, and myocardial @entity2 ( @entity2 ) were measured. The LV FFR and average slope were derived from the @entity2 measured at different heart rates during supine bicycle exercise. Blood pressures at rest were similar between @entity0 and controls (all p >0.05). At baseline, @entity0 compared with controls had significantly greater E velocity, E/A and E/em ratios, and lower sm and em velocities (all p <0.05) but similar @entity2 (p  = 0.18). At submaximal exercise, diastolic (p  = 0.001) and mean (p  = 0.003) blood pressures became significantly higher in @entity0 than controls, sm (p  = 0.001) and em (p <0.001) velocities remained reduced, whereas the @entity2 became lower (p <0.001). The weighted average FFR was flattened (p <0.001), and average FFR slope was lower (p <0.001) in @entity0 compared with controls. The average FFR slope correlated negatively with the magnitude of exercise-induced increase in systolic (r  =  -0.32, p  = 0.050), mean (r  =  -0.41, p  = 0.011), and diastolic (r  =  -0.40, p  = 0.013) blood pressures. In conclusion, young adults after @entity1 and interrupted aortic arch repair exhibit reduced LV contractile reserve, which is related to the blood pressure response during exercise stress.

title: Left Ventricular Contractile Reserve in Young Adults Long-Term After Repair of XXXX .

answer: @entity1


abstract: Effects of @entity5 ( @entity5 ) and @entity4 ( @entity4 ) on @entity6 ( @entity1 ) levels were studied in the isolated @entity0 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity5 increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity4 also increased the levels at the same concentration range, but @entity5 was more potent than @entity4 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity14 (10(-6) M) on @entity1 levels were antagonized by the @entity11 receptor antagonist @entity12 , 2 x 10(-6) M, and the ETB receptor agonist @entity13 evoked only a weak increase in @entity1 levels. Moreover, the effects of @entity14 were completely abolished by the cyclooxygenase inhibitor @entity9 , 2 x 10(-5) M. On the other hand, among @entity8 , @entity2 ( @entity2 ) increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity3 and @entity10 did not exhibit such effects. @entity2 levels were increased by application of @entity5 (10(-8)-10(-5) M). The @entity5 -induced @entity2 accumulation was strongly inhibited by @entity9 and @entity12 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity7 also elevated the @entity1 level by approximately 9-fold above the basal @entity1 level. After @entity7 , @entity5 failed to increase @entity2 and @entity1 levels. In the intermediate-posterior pituitary, @entity14 did not affect @entity1 levels. The results suggest that endothelins increase @entity1 levels via @entity11 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity2 production is involved in the @entity0 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate XXXX accumulation in the isolated @entity0 anterior pituitary gland: possible involvement of @entity11 receptor activation and @entity2 production.

answer: @entity6


abstract: Effects of @entity5 ( @entity5 ) and @entity4 ( @entity4 ) on @entity6 ( @entity1 ) levels were studied in the isolated @entity0 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity5 increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity4 also increased the levels at the same concentration range, but @entity5 was more potent than @entity4 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity14 (10(-6) M) on @entity1 levels were antagonized by the @entity11 receptor antagonist @entity12 , 2 x 10(-6) M, and the ETB receptor agonist @entity13 evoked only a weak increase in @entity1 levels. Moreover, the effects of @entity14 were completely abolished by the cyclooxygenase inhibitor @entity9 , 2 x 10(-5) M. On the other hand, among @entity8 , @entity2 ( @entity2 ) increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity3 and @entity10 did not exhibit such effects. @entity2 levels were increased by application of @entity5 (10(-8)-10(-5) M). The @entity5 -induced @entity2 accumulation was strongly inhibited by @entity9 and @entity12 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity7 also elevated the @entity1 level by approximately 9-fold above the basal @entity1 level. After @entity7 , @entity5 failed to increase @entity2 and @entity1 levels. In the intermediate-posterior pituitary, @entity14 did not affect @entity1 levels. The results suggest that endothelins increase @entity1 levels via @entity11 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity2 production is involved in the @entity0 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate @entity6 accumulation in the isolated @entity0 anterior pituitary gland: possible involvement of @entity11 receptor activation and XXXX production.

answer: @entity2


abstract: Effects of @entity5 ( @entity5 ) and @entity4 ( @entity4 ) on @entity6 ( @entity1 ) levels were studied in the isolated @entity0 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity5 increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity4 also increased the levels at the same concentration range, but @entity5 was more potent than @entity4 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity14 (10(-6) M) on @entity1 levels were antagonized by the @entity11 receptor antagonist @entity12 , 2 x 10(-6) M, and the ETB receptor agonist @entity13 evoked only a weak increase in @entity1 levels. Moreover, the effects of @entity14 were completely abolished by the cyclooxygenase inhibitor @entity9 , 2 x 10(-5) M. On the other hand, among @entity8 , @entity2 ( @entity2 ) increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity3 and @entity10 did not exhibit such effects. @entity2 levels were increased by application of @entity5 (10(-8)-10(-5) M). The @entity5 -induced @entity2 accumulation was strongly inhibited by @entity9 and @entity12 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity7 also elevated the @entity1 level by approximately 9-fold above the basal @entity1 level. After @entity7 , @entity5 failed to increase @entity2 and @entity1 levels. In the intermediate-posterior pituitary, @entity14 did not affect @entity1 levels. The results suggest that endothelins increase @entity1 levels via @entity11 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity2 production is involved in the @entity0 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate @entity6 accumulation in the isolated @entity0 anterior pituitary gland: possible involvement of XXXX receptor activation and @entity2 production.

answer: @entity11


abstract: Effects of @entity5 ( @entity5 ) and @entity4 ( @entity4 ) on @entity6 ( @entity1 ) levels were studied in the isolated @entity0 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity5 increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity4 also increased the levels at the same concentration range, but @entity5 was more potent than @entity4 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity14 (10(-6) M) on @entity1 levels were antagonized by the @entity11 receptor antagonist @entity12 , 2 x 10(-6) M, and the ETB receptor agonist @entity13 evoked only a weak increase in @entity1 levels. Moreover, the effects of @entity14 were completely abolished by the cyclooxygenase inhibitor @entity9 , 2 x 10(-5) M. On the other hand, among @entity8 , @entity2 ( @entity2 ) increased @entity1 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity3 and @entity10 did not exhibit such effects. @entity2 levels were increased by application of @entity5 (10(-8)-10(-5) M). The @entity5 -induced @entity2 accumulation was strongly inhibited by @entity9 and @entity12 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity7 also elevated the @entity1 level by approximately 9-fold above the basal @entity1 level. After @entity7 , @entity5 failed to increase @entity2 and @entity1 levels. In the intermediate-posterior pituitary, @entity14 did not affect @entity1 levels. The results suggest that endothelins increase @entity1 levels via @entity11 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity2 production is involved in the @entity0 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate @entity6 accumulation in the isolated XXXX anterior pituitary gland: possible involvement of @entity11 receptor activation and @entity2 production.

answer: @entity0


abstract: Bath @entity4 Activity Index (BASDAI) is the most frequently used @entity4 activity assesment by which through 6 questions 5 basic diseases symptoms ( @entity3 , @entity2 , @entity1 /swelling, enthesitic points, intensity and duration of @entity6 ) are being evaluated. In distinction from mentioned, @entity4 Activity Score (ASDAS) is the first validated index for the @entity5 activity assessment with the @entity0 's assessments of the disease symptoms ( @entity2 , duration of the morning stiffess, activity of the disease, @entity1 ) includes the acute phase reactants (SE or CRP). We compared BASDAI and ASDAS indexes to the group of @entity0 with the @entity5 , in order to evaluate their congruence and to evaluate the inluence of @entity2 at obtained values. The cross-sectional study was performed in a group of 36 @entity0 with the @entity5 whose disease activity levels were evaluated by the BASDAI and ASDAS (SE) index. Statistical data analysis was performed by Student t-test and frequency tables for non-parameter data. As it has been expected the significant correlation between BASDAI and ASDAS indexes has been confirmed (r=0.796; p=0.00). BASDAI/ASDAS average value of all of the @entity0 was 4.2/2.8. From 36 @entity0 with the @entity5 according to the BASDAI index 42% had mild active disease (BASDAI <4), while according to ASDAS index 44% @entity0 had very active disease (ASDAS 2.1-.5.3). Higher activity of the disease according to ASDAS index is the result of the elevated sedimentation which is assessed only in ASDAS index. @entity0 with higher BASDAI index statistically have more significantly expressed @entity3 and @entity1 without statistically significant difference in sedimentation (p=0.120). Examinees with higher ASDAS index have also significantly more expressed @entity2 , but unlike BASDAI they have sedimentation (p=0.001). ASDAS is more recent clinical indicator of the @entity5 activities which could be compared to BASDAI instrument. In this group of @entity0 ASDAS seems to be more sensitive index because it discriminates more @entity0 with the active disease.

title: [Scoring of disease activity using BASDAI and ASDAS method in XXXX ].

answer: @entity4


abstract: The classification of @entity0 residues based on the events of contact formation between distinct @entity0 and selected @entity2 was constructed. Thus, the most integral properties, that characterize interactions in organization of DNA-protein complexes, were used. We applied the Voronoi-Delaunay tessellation to draw statistics of contacts and area of contacts for the set included 1937 DNA-protein complexes. Similarities of @entity0 residues have been searched for based on the comparison of corresponded rows and matrixes of contacts and areas of contacts. Nine measures of distance were used for estimation of rows similarity degree. The procedure of clustering @entity1 in groups included three hierarchical and two nonhierarchical methods. A total tree was built using nine techniques of estimating distance with three hierarchical clustering methods. It was shown that clustering centers in the main groups are always constant while other relationships between objects vary. Clustering of binary associations was found for the most @entity1 . Major classes of up to six @entity1 correspond to the certain local structures of the polypeptide chain in the context of @entity0 composition. These data should be taken into account when designing DNA-protein ligands.

title: [Classification of XXXX based on a comparative analysis of contacts in DNA-protein complexes and specific DNA-protein interactions].

answer: @entity1


abstract: @entity3 ( @entity3 ) is @entity4 in mammals and is a potent coronary vasodilator. @entity6 ( @entity6 ) has been reported to have similar vascular activity. In the present study, the effects of @entity0 @entity3 ( @entity3 ) and @entity0 @entity6 (hPTHrp) were compared in various in vivo and in vitro assays. In vivo studies included blood pressure measurement and coronary blood flow determination with labeled microspheres in anesthetized and cannulated normotensive @entity1 . Isolated @entity1 tail artery and portal vein helical strips were used in studying tension development in vitro. In the blood pressure assay, @entity6 was several times more potent than @entity3 . @entity6 was also significantly more potent than @entity3 in relaxing tail artery precontracted with @entity7 ( @entity5 ). @entity6 and @entity3 both inhibited the spontaneously contracting portal vein, but again @entity6 was significantly more potent. @entity6 (1 microgram/kg) produced a greater increase in coronary blood flow as compared with the same dose of @entity3 . These data suggest that @entity6 is more potent than @entity3 in its cardiovascular actions. It is possible that @entity6 is the endogenous vasodilating ligand, and the structural similarity between @entity3 and @entity6 may explain the pharmacological action of @entity3 . It is therefore unlikely that @entity3 or @entity6 may be involved in the genesis or maintenance of @entity2 . Because the parathyroid gland seems to be involved in some forms of essential @entity2 , factor(s) other than @entity3 or @entity6 may be responsible.

title: Cardiovascular effects of @entity0 @entity3 and XXXX -related peptide.

answer: @entity3


abstract: @entity3 ( @entity3 ) is @entity4 in mammals and is a potent coronary vasodilator. @entity6 ( @entity6 ) has been reported to have similar vascular activity. In the present study, the effects of @entity0 @entity3 ( @entity3 ) and @entity0 @entity6 (hPTHrp) were compared in various in vivo and in vitro assays. In vivo studies included blood pressure measurement and coronary blood flow determination with labeled microspheres in anesthetized and cannulated normotensive @entity1 . Isolated @entity1 tail artery and portal vein helical strips were used in studying tension development in vitro. In the blood pressure assay, @entity6 was several times more potent than @entity3 . @entity6 was also significantly more potent than @entity3 in relaxing tail artery precontracted with @entity7 ( @entity5 ). @entity6 and @entity3 both inhibited the spontaneously contracting portal vein, but again @entity6 was significantly more potent. @entity6 (1 microgram/kg) produced a greater increase in coronary blood flow as compared with the same dose of @entity3 . These data suggest that @entity6 is more potent than @entity3 in its cardiovascular actions. It is possible that @entity6 is the endogenous vasodilating ligand, and the structural similarity between @entity3 and @entity6 may explain the pharmacological action of @entity3 . It is therefore unlikely that @entity3 or @entity6 may be involved in the genesis or maintenance of @entity2 . Because the parathyroid gland seems to be involved in some forms of essential @entity2 , factor(s) other than @entity3 or @entity6 may be responsible.

title: Cardiovascular effects of @entity0 XXXX and @entity3 -related peptide.

answer: @entity3


abstract: @entity3 ( @entity3 ) is @entity4 in mammals and is a potent coronary vasodilator. @entity6 ( @entity6 ) has been reported to have similar vascular activity. In the present study, the effects of @entity0 @entity3 ( @entity3 ) and @entity0 @entity6 (hPTHrp) were compared in various in vivo and in vitro assays. In vivo studies included blood pressure measurement and coronary blood flow determination with labeled microspheres in anesthetized and cannulated normotensive @entity1 . Isolated @entity1 tail artery and portal vein helical strips were used in studying tension development in vitro. In the blood pressure assay, @entity6 was several times more potent than @entity3 . @entity6 was also significantly more potent than @entity3 in relaxing tail artery precontracted with @entity7 ( @entity5 ). @entity6 and @entity3 both inhibited the spontaneously contracting portal vein, but again @entity6 was significantly more potent. @entity6 (1 microgram/kg) produced a greater increase in coronary blood flow as compared with the same dose of @entity3 . These data suggest that @entity6 is more potent than @entity3 in its cardiovascular actions. It is possible that @entity6 is the endogenous vasodilating ligand, and the structural similarity between @entity3 and @entity6 may explain the pharmacological action of @entity3 . It is therefore unlikely that @entity3 or @entity6 may be involved in the genesis or maintenance of @entity2 . Because the parathyroid gland seems to be involved in some forms of essential @entity2 , factor(s) other than @entity3 or @entity6 may be responsible.

title: Cardiovascular effects of XXXX @entity3 and @entity3 -related peptide.

answer: @entity0


abstract: UNASSIGNED: Quantification by mass spectrometry imaging (Q- @entity1 ) is one of the hottest topics of the current discussions among the experts of the @entity0 imaging community. If @entity1 is established as a powerful qualitative tool in drug and biomarker discovery, its reliability for absolute and accurate quantification (QUAN) is still controversial. Indeed, Q- @entity1 has to deal with several fundamental aspects that are difficult to control, and to account for absolute quantification. The first objective of this manuscript is to review the state-of-the-art of  Q- @entity1 and the current strategies developed for absolute quantification by direct surface sampling from tissue sections. This includes comments on the quest for the perfect matrix-matched standards and signal normalization approaches. Furthermore, this work investigates quantification at a pixel level to determine how many pixels must be considered for accurate quantification by ultraviolet matrix-assisted laser desorption/ionization (MALDI), the most widely used technique for @entity1 . Particularly, this study focuses on the MALDI-selected reaction monitoring (SRM) in rastering mode, previously demonstrated as a quantitative and robust approach for small analyte and peptide-targeted analyses. The importance of designing experiments of good quality and the use of a labeled compound for signal normalization is emphasized to minimize the signal variability. This is exemplified by measuring the signal for cocaine and a tryptic peptide (i.e., obtained after digestion of a monoclonal antibody) upon different experimental conditions, such as sample stage velocity, laser power and frequency, or distance between two raster lines. Our findings show that accurate quantification cannot be performed on a single pixel but requires averaging of at least 4-5  pixels. The present work demonstrates that MALDI-SRM/ @entity1 is quantitative with precision better than 10-15  %, which meets the requirements of most guidelines (i.e., in bioanalysis or toxicology) for quantification of drugs or peptides from tissue homogenates.

title: Quantification in MALDI- XXXX imaging: what can we learn from MALDI-selected reaction monitoring and what can we expect for imaging?

answer: @entity0


abstract: Several chromosomal rearrangements involving band 3q26 are known to induce @entity3 overexpression. They include inv(3)(q21q26), t(3;3)(q21;q26), t(3;21)(q26;q22) and t(3;12)(q26;p13). Translocations involving the short arm of chromosome 2 and 3q26 have been reported in more than 50 @entity0 with @entity1 . However, although the breakpoints on 2p are scattered over a long segment, their distribution had only been analyzed in 9 @entity0 . We performed fluorescent in situ hybridization with a library of BAC (Bacterial Artificial Chromosome) clones in 4 @entity0 with t(2;3)(p15-23;q26). Our results combined with those of the 9 previously reported @entity0 showed scattering of the breakpoints in 2 regions. A 1.08Mb region in band 2p21 encompassing the @entity6 , @entity5 and @entity4 genes was documented in 5 @entity0 . A second region of 1.83Mb in band 2p16.1 was identified in 8 @entity0 . Four @entity0 showed clustering around the @entity2 gene and the remaining 4 around a long intergenic non-coding RNA, FLJ30838. These regions are characterized by the presence of regulatory sequences (CpG islands and promoters) that could be instrumental in @entity3 overexpression.

title: Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving XXXX in myeloid hemopathies.

answer: @entity3


abstract: In @entity2 , the epidermis contains large clear neoplastic cells. To explain the pathogenesis of this disease, the immunohistochemical characteristics of these cells were investigated in 25 @entity1 . The cytoplasmic presence of low molecular weight cytokeratin and the absence of high molecular weight cytokeratin in all cases confirmed the glandular origin of the Paget cells. Membrane over-expression of the @entity4 -protein was established in 96% of cases. It was hypothesized that epidermal keratinocytes release a chemotactic factor which attracts @entity4 -over-expressing @entity0 cells by @entity3 into the epidermis. The biological assays showed that normal keratinocytes release one or more chemotactic factor(s) into their conditioned medium, which induced spreading and motility of @entity4 -over-expressing SK-BR-3 @entity1 @entity0 cells. The conditioned medium of keratinocytes also attracted the SK-BR-3 cells by @entity3 in a modified Boyden chamber. Furthermore, MCF-7 @entity1 @entity0 cells, which do not over-express the @entity4 -protein, were not attracted by @entity3 of conditioned medium of @entity1 keratinocytes. The involvement of the @entity4 -protein in spreading, motility and @entity3 is further indicated by the inhibition of these processes by monoclonal antibodies against the extracellular domain of the @entity4 -protein. We conclude, therefore, that the Paget cells spread through the epidermis due to the motility induced by a chemotactic factor, which is released by epidermal keratinocytes and whose influence is mediated by the @entity4 -protein.

title: Keratinocyte induced XXXX in the pathogenesis of @entity2 .

answer: @entity3


abstract: In @entity2 , the epidermis contains large clear neoplastic cells. To explain the pathogenesis of this disease, the immunohistochemical characteristics of these cells were investigated in 25 @entity1 . The cytoplasmic presence of low molecular weight cytokeratin and the absence of high molecular weight cytokeratin in all cases confirmed the glandular origin of the Paget cells. Membrane over-expression of the @entity4 -protein was established in 96% of cases. It was hypothesized that epidermal keratinocytes release a chemotactic factor which attracts @entity4 -over-expressing @entity0 cells by @entity3 into the epidermis. The biological assays showed that normal keratinocytes release one or more chemotactic factor(s) into their conditioned medium, which induced spreading and motility of @entity4 -over-expressing SK-BR-3 @entity1 @entity0 cells. The conditioned medium of keratinocytes also attracted the SK-BR-3 cells by @entity3 in a modified Boyden chamber. Furthermore, MCF-7 @entity1 @entity0 cells, which do not over-express the @entity4 -protein, were not attracted by @entity3 of conditioned medium of @entity1 keratinocytes. The involvement of the @entity4 -protein in spreading, motility and @entity3 is further indicated by the inhibition of these processes by monoclonal antibodies against the extracellular domain of the @entity4 -protein. We conclude, therefore, that the Paget cells spread through the epidermis due to the motility induced by a chemotactic factor, which is released by epidermal keratinocytes and whose influence is mediated by the @entity4 -protein.

title: Keratinocyte induced @entity3 in the pathogenesis of XXXX .

answer: @entity2


abstract: BACKGROUND: @entity7 at several sites (multisite @entity5 ) is more common than single-site @entity5 . Little is known on its effects on @entity6 ( @entity6 ) retirement. METHODS: A nationally representative sample comprised 4071 Finns in the workforce aged 30 to 63. Data (questionnaire, interview, clinical examination) were gathered in 2000-2001 and linked with national @entity6 registers for 2000-2011. @entity5 during the preceding month in 18 locations was combined into four sites (neck, upper limbs, low back, lower limbs). Hazard ratios (HR) of @entity6 were estimated by Cox regression. RESULTS: The HR of any @entity6 (n   =   477) was 1.6 (95% confidence interval 1.2-2.1) for one, 2.5 (1.9-3.3) for two, 3.1 (2.3-4.3) for three and 5.6 (4.0-7.8) for four @entity5 sites, when adjusted for age and gender. When additionally adjusted for clinically assessed @entity3 , the HRs varied from 1.4 (1.0-1.8) to 3.5 (2.5-4.9), respectively. When further adjusted for physical and psychosocial workload, education, body mass index, smoking, exercise and @entity0 , the HRs were 1.3 (0.9-1.7), 1.6 (1.2-2.2), 1.8 (1.3-2.5) and 2.5 (1.8-3.6). The number of @entity5 sites was especially strong in predicting DPs due to @entity2 (HRs in the full model; 3.1 to 4.3), but it also predicted DPs due to other @entity1 (respective HRs 1.3 to 2.3); @entity5 in all four sites was also predictive of DPs due to @entity4 (full model HR 2.2). CONCLUSIONS: The number of @entity5 sites independently predicted @entity6 retirement. Employees with multisite @entity5 may need specific support to maintain their work ability.

title: Multisite XXXX predicts medically certified disability retirement among Finns.

answer: @entity7


abstract: BACKGROUND/PURPOSE: The purpose of this study was to investigate effects of risk factors on recurrence of @entity2 ( @entity2 ). METHODS: A retrospective review was conducted of 107 SCTs treated between January 2003 and December 2012 in our center. Risk factors were identified by univariate and multivariate analysis. RESULTS: Sixteen @entity0 had recurrence of @entity2 a median interval of 16.25months after primary surgery. 15.6% @entity1 recurrence were Altman type I, 10.5% type II, 10.0% type III, and 31.3% type IV. The recurrence of mature @entity2 was observed in 8 @entity0 , immature in 2, malignant in 5. More than half of the recurrences showed a shift towards histological immaturity or @entity1 , compared with the @entity1 pathology. Risk factors for recurrence were spillage of @entity1 parenchyma during operation (P=0.028), incomplete resection (p=0.000), and primary immature (P=0.029) and malignant histology (P=0.026). Size, Altman classification, and age were not risk factors for recurrence. There was a statistically significant difference in OS between @entity0 who developed relapse (64.8%) and those who did not (95.0%) (P=0.0002). CONCLUSIONS: @entity1 recurrence affected the outcome of @entity0 with @entity2 . Risk factors were @entity1 spillage, immature and malignant histology, or incomplete resection. Regular follow-up after surgery is mandatory to find @entity1 relapse earlier and to improve the outcome.

title: Analysis of recurrence risks for XXXX in @entity0 .

answer: @entity2


abstract: BACKGROUND/PURPOSE: The purpose of this study was to investigate effects of risk factors on recurrence of @entity2 ( @entity2 ). METHODS: A retrospective review was conducted of 107 SCTs treated between January 2003 and December 2012 in our center. Risk factors were identified by univariate and multivariate analysis. RESULTS: Sixteen @entity0 had recurrence of @entity2 a median interval of 16.25months after primary surgery. 15.6% @entity1 recurrence were Altman type I, 10.5% type II, 10.0% type III, and 31.3% type IV. The recurrence of mature @entity2 was observed in 8 @entity0 , immature in 2, malignant in 5. More than half of the recurrences showed a shift towards histological immaturity or @entity1 , compared with the @entity1 pathology. Risk factors for recurrence were spillage of @entity1 parenchyma during operation (P=0.028), incomplete resection (p=0.000), and primary immature (P=0.029) and malignant histology (P=0.026). Size, Altman classification, and age were not risk factors for recurrence. There was a statistically significant difference in OS between @entity0 who developed relapse (64.8%) and those who did not (95.0%) (P=0.0002). CONCLUSIONS: @entity1 recurrence affected the outcome of @entity0 with @entity2 . Risk factors were @entity1 spillage, immature and malignant histology, or incomplete resection. Regular follow-up after surgery is mandatory to find @entity1 relapse earlier and to improve the outcome.

title: Analysis of recurrence risks for @entity2 in XXXX .

answer: @entity0


abstract: @entity0 with the @entity4 Syndrome (POTS) have orthostatic intolerance, as well as exercise intolerance. Peak @entity1 uptake (VO2peak) is generally lower in these @entity0 compared with healthy sedentary individuals, suggesting a lower physical fitness level. During acute exercise, POTS @entity0 have an excessive increase in heart rate and reduced @entity2 volume for each level of absolute workload; however, when expressed at relative workload (%VO2peak), there is no difference in the heart rate response between @entity0 and healthy individuals. The relationship between cardiac output and VO2 is similar between POTS @entity0 and healthy individuals. Short-term (i.e., 3months) exercise training increases cardiac size and mass, blood volume, and VO2peak in POTS @entity0 . Exercise performance is improved after training. Specifically, @entity2 volume is greater and heart rate is lower at any given VO2 during exercise after training versus before training. Peak heart rate is the same but peak @entity2 volume and cardiac output are greater after training. Heart rate recovery from peak exercise is significantly faster after training, indicating an improvement in autonomic circulatory control. These results suggest that @entity0 with POTS have no intrinsic abnormality of heart rate regulation during exercise. The @entity3 in POTS is due to a reduced @entity2 volume. Cardiac remodeling and blood volume expansion associated with exercise training increase physical fitness and improve exercise performance in these @entity0 .

title: Exercise in the postural XXXX .

answer: @entity3


abstract: This study presents the results of the response of Sparus aurata to three different musical stimuli, derived from the transmission (4  h per day, 5  days per week) of particular music pieces by Mozart, Romanza and @entity5 (140  dBrms re 1   Pa), compared to the same transmission level of white noise, while the underwater ambient noise in all the experimental tanks was 121  dBrms re 1   Pa. Using recirculating sea water facilities, 10 groups, 2 for each treatment, of 20 specimens of 11.2      0.02  g (S.E.), were reared for 94  days, under 150      10  l* 12L-12D, and were fed an artificial diet three times per day. Fish body weight showed significant differences after 55  days, while its maximum level was observed after the 69th day until the end of the experiment, the highest value demonstrated in Mozart (M) groups, followed by those of Romanza (R), @entity5 (B), control (C) and white noise (WN). SGR (M  =  B), %WG (M  =  B) and FCR (all groups fed same % b.w.) were also improved for M group. Brain neurotransmitters results exhibited significant differences in DA- @entity0 , (M  >  B), @entity4 (C  >  B), 5HIAA:5HT (WN  >  R), @entity3 (M  >  B), @entity3 :DA and ( @entity3  +  @entity2 ):DA, (C  >  M), while no significant differences were observed in 5HT, NA, @entity2 and @entity2 :DA. No differences were observed in biometric measurements, protease activity, % @entity1 of fillet, visceral fat and liver, while differences were observed regarding carbohydrase activity and the amount (mg/g w.w.) of some @entity1 in liver, fillet and visceral fat. In conclusion, present results confirm those reported for S. aurata, concerning the observed relaxing influence-due to its brain neurotransmitters action-of the transmission of Mozart music (compared to R and B), which resulted in the achievement of maximum growth rate, body weight and improved FCR. This conclusion definitely supports the musical "understanding" and sensitivity of S. aurata to music stimuli as well as suggesting a specific effect of white noise.

title: Gilthead seabream (Sparus aurata) response to three music stimuli (Mozart-"Eine Kleine Nachtmusik," Anonymous-"Romanza," XXXX -"Violin Concerto No. 1") and white noise under recirculating water conditions.

answer: @entity5


abstract: We retrospectively reviewed 46 @entity0 with superior @entity3 during the period 1986-1992. The common symptoms included congestion of collateral veins of the neck, anterior chest wall, face, eyelids and right arm. Dyspoea and @entity2 occurred less frequently. In all but two @entity0 a histological diagnosis was made by invasive and non-invasive examination without complications. In 82% of all @entity0 a primary @entity1 was the cause of the superior @entity3 . For 39 @entity0 radiotherapy was the first treatment of choice. To relieve the distressing symptoms @entity0 received one of two regimens employing hypofractionated radiotherapy. In regimen 3F, 25 @entity0 received three weekly high dose fractions of 8 Gy delivering a total dose of 24 Gy. Regimen 2F, applied to seven @entity0 , consisted of two weekly fractions of 8 Gy, giving a total of 24 Gy. In both regimens a good palliative result was established, however the results of the 3F regimen were superior. Using the 3F regimen a partial response was obtained in 96% of all @entity0 , and 56% achieved a complete response. With the 2F regimen a partial response was achieved in 70% of all @entity0 , and a complete response in only 28%. Minimal side effects were noted. After reviewing our experience, the 3F regimen is recommended for rapid and effective relief of the superior @entity3 .

title: Hypofractionated radiation therapy in the treatment of superior XXXX .

answer: @entity3


abstract: UNASSIGNED: Patch mosaic burning, in which fire is used to produce a mosaic of habitat patches representative of a range of fire histories ('pyrodiversity'), has been widely advocated to promote greater biodiversity. However, the details of desired fire mosaics for prescribed burning programs are often unspecified. Threatened small to medium-sized mammals (35 g to 5.5 kg) in the fire-prone tropical savannas of Australia appear to be particularly fire-sensitive. Consequently, a clear understanding of which properties of fire mosaics are most instrumental in influencing savanna @entity0 populations is critical. Here we use @entity0 capture data, remotely sensed fire information (i.e. time since last fire, fire frequency, frequency of late dry season fires, diversity of post-fire ages in 3 km radius, and spatial extent of recently burnt, intermediate and long unburnt habitat) and structural habitat attributes (including an index of @entity2 disturbance) to examine which characteristics of fire mosaics most influence mammals in the north-west Kimberley. We used general linear models to examine the relationship between fire mosaic and habitat attributes on total @entity0 abundance and richness, and the abundance of the most commonly detected species. Strong negative associations of @entity0 abundance and richness with frequency of late dry season fires, the spatial extent of recently burnt habitat (post-fire age <1 year within 3 km radius) and level of @entity2 disturbance were observed. Shrub cover was positively related to both @entity0 abundance and richness, and availability of rock crevices, ground @entity1 cover and spatial extent of >= 4 years unburnt habitat were all positively associated with at least some of the @entity0 species modelled. We found little support for diversity of post-fire age classes in the models. Our results indicate that both a high frequency of intense late dry season fires and extensive, recently burnt @entity1 are likely to be detrimental to mammals in the north Kimberley. A managed fire mosaic that reduces large scale and intense fires, including the retention of >= 4 years unburnt patches, will clearly benefit savanna mammals. We also highlighted the importance of fire mosaics that retain sufficient shelter for mammals. Along with fire, it is clear that grazing by introduced herbivores also needs to be reduced so that habitat quality is maintained.

title: Influence of Fire Mosaics, Habitat Characteristics and XXXX Disturbance on Mammals in Fire-Prone Savanna Landscapes of the Northern Kimberley.

answer: @entity2


abstract: BACKGROUND _ AIMS: @entity5 , best known to regulate bone mineralization, has numerous additional roles including regulation inflammatory pathways. Recently, an increased incidence of @entity8 ( @entity7 ) deficiency has been found in subjects suffering from @entity4 . We here investigated if low @entity5 levels might be associated with prognosis, @entity1 and @entity3 in @entity0 with @entity2 . METHODS: We performed a prospective cohort study investigating the relation between @entity7 levels and stages of @entity2 , mortality and complications of @entity2 , including infections. RESULTS: 251 @entity0 with @entity2 were enrolled into the present prospective cohort study. @entity7 levels were quantified by radioimmunoassay from serum samples obtained at study inclusion. The mean follow-up time was 411    397 days with a range of 1-1382 days. 30 (12.0%) @entity0 underwent liver transplantation and 85 (33.8%) individuals died within the study. The mean serum @entity7 concentration was 8.93    7.1 ng/ml with a range of 1.0 to 46.0 ng/ml. @entity7 levels differed significantly between @entity0 Pugh scores and showed a negative correlation with the @entity6 ( @entity6 ) score. @entity0 with decompensated @entity2 and @entity3 , had significantly lower @entity7 levels compared to subjects without complications. Low @entity7 was associated with mortality in uni- as well as multivariate Cox regression models. CONCLUSIONS: @entity7 deficiency is associated with advanced @entity4 and low @entity7 levels are an indicator for a poor outcome and are associated with @entity3 .

title: Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in @entity0 with XXXX .

answer: @entity2


abstract: BACKGROUND _ AIMS: @entity5 , best known to regulate bone mineralization, has numerous additional roles including regulation inflammatory pathways. Recently, an increased incidence of @entity8 ( @entity7 ) deficiency has been found in subjects suffering from @entity4 . We here investigated if low @entity5 levels might be associated with prognosis, @entity1 and @entity3 in @entity0 with @entity2 . METHODS: We performed a prospective cohort study investigating the relation between @entity7 levels and stages of @entity2 , mortality and complications of @entity2 , including infections. RESULTS: 251 @entity0 with @entity2 were enrolled into the present prospective cohort study. @entity7 levels were quantified by radioimmunoassay from serum samples obtained at study inclusion. The mean follow-up time was 411    397 days with a range of 1-1382 days. 30 (12.0%) @entity0 underwent liver transplantation and 85 (33.8%) individuals died within the study. The mean serum @entity7 concentration was 8.93    7.1 ng/ml with a range of 1.0 to 46.0 ng/ml. @entity7 levels differed significantly between @entity0 Pugh scores and showed a negative correlation with the @entity6 ( @entity6 ) score. @entity0 with decompensated @entity2 and @entity3 , had significantly lower @entity7 levels compared to subjects without complications. Low @entity7 was associated with mortality in uni- as well as multivariate Cox regression models. CONCLUSIONS: @entity7 deficiency is associated with advanced @entity4 and low @entity7 levels are an indicator for a poor outcome and are associated with @entity3 .

title: Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in XXXX with @entity2 .

answer: @entity0


abstract: AIM: In recent years, several studies with large sample sizes and recent follow-up data have been published comparing outcomes between laparoscopic Nissen fundoplication and laparoscopic Toupet fundoplication. It is now timely to be re-evaluated and synthesized long-term efficacy and adverse events of both total and partial posterior fundoplication. MATERIALS AND METHODS: Electronic searches for RCTs comparing the outcome after laparoscopic Nissen fundoplication and laparoscopic Toupet fundoplication were performed in the databases of MEDLINE, EMBASE, and the Cochrane Center Register of Controlled Trials. The data of evaluation in positive and adverse results of laparoscopic Nissen fundoplication and laparoscopic Nissen fundoplication were extracted and compared using meta-analysis. RESULTS: 13 RCTs were ultimately identified involving 814 (52.05%) and 750 (47.95%) @entity0 who underwent laparoscopic Nissen fundoplication and laparoscopic Toupet fundoplication, respectively. The operative time, perioperative complications, @entity1 , recurrence, and the rates of medication adoption or re-operation due to recurrence were not significantly different between two groups. The two types of fundoplication both reinforced the anti-reflux barrier and elevated the lower esophageal sphincter pressure. However, rates of adverse results involving @entity3 , @entity4 , inability to belch and re-operation due to severe @entity3 were significantly higher after LNF. In the subgroup analysis of wrap length <=2cm, laparoscopic Nissen fundoplication was associated with a significantly higher incidence of @entity1 . However, in the subgroup wrap length>2cm, the difference was not statistically significant. CONCLUSION: Laparoscopic Toupet fundoplication might be the better surgery approach for @entity2 with a lower rate of postoperative adverse results and equal effectiveness as Laparoscopic Nissen fundoplication.

title: A Meta-Analysis of Randomized Controlled Trials to Compare Long-Term Outcomes of Nissen and Toupet Fundoplication for XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity0 skin colour, ie @entity4 , differs widely among individuals, as do their responses to various types of ultraviolet radiation (UV) and their risks of @entity1 . In some individuals, UV-induced @entity4 persists for months to years in a phenomenon termed long-lasting @entity4 (LLP). It is unclear whether LLP is an indicator of potential risk for @entity1 . LLP seems to have similar features to other forms of @entity3 , eg solar lentigines or age spots, which are clinical markers of photodamage and risk factors for @entity2 . To investigate what UV-induced molecular changes may persist in individuals with LLP, clinical specimens from non-sunburn-inducing repeated UV exposures (UVA, UVB or UVA + UVB) at 4 months post-exposure (short-term LLP) were evaluated by microarray analysis and dataset mining. Validated targets were further evaluated in clinical specimens from six healthy individuals (three LLP+ and three LLP-) followed for more than 9 months (long-term LLP) who initially received a single sunburn-inducing UVA + UVB exposure. The results support a UV-induced @entity3 model in which basal keratinocytes have an impaired ability to remove melanin that leads to a compensatory mechanism by neighbouring keratinocytes with increased proliferative capacity to maintain skin homeostasis. The attenuated expression of @entity6 and other hemidesmosomal components ( @entity5 ) leads to increased melanosome uptake by keratinocytes and points to a spatial regulation within the epidermis. The reduced density of hemidesmosomes provides supporting evidence for plasticity at the epidermal-dermal junction. Altered hemidesmosome plasticity, and the sustained nature of LLP, may be mediated by the role of @entity6 in basal keratinocytes. The long-term sustained subtle changes detected are modest, but sufficient to create dramatic visual differences in skin colour. These results suggest that the @entity3 phenomenon leading to increased interdigitation develops in order to maintain normal skin homeostasis in individuals with LLP. Copyright    2014 Pathological Society of Great Britain and Ireland. Published by John Wiley _ Sons, Ltd.

title: UV exposure modulates hemidesmosome plasticity, contributing to long-term XXXX in @entity0 skin.

answer: @entity4


abstract: UNASSIGNED: @entity0 skin colour, ie @entity4 , differs widely among individuals, as do their responses to various types of ultraviolet radiation (UV) and their risks of @entity1 . In some individuals, UV-induced @entity4 persists for months to years in a phenomenon termed long-lasting @entity4 (LLP). It is unclear whether LLP is an indicator of potential risk for @entity1 . LLP seems to have similar features to other forms of @entity3 , eg solar lentigines or age spots, which are clinical markers of photodamage and risk factors for @entity2 . To investigate what UV-induced molecular changes may persist in individuals with LLP, clinical specimens from non-sunburn-inducing repeated UV exposures (UVA, UVB or UVA + UVB) at 4 months post-exposure (short-term LLP) were evaluated by microarray analysis and dataset mining. Validated targets were further evaluated in clinical specimens from six healthy individuals (three LLP+ and three LLP-) followed for more than 9 months (long-term LLP) who initially received a single sunburn-inducing UVA + UVB exposure. The results support a UV-induced @entity3 model in which basal keratinocytes have an impaired ability to remove melanin that leads to a compensatory mechanism by neighbouring keratinocytes with increased proliferative capacity to maintain skin homeostasis. The attenuated expression of @entity6 and other hemidesmosomal components ( @entity5 ) leads to increased melanosome uptake by keratinocytes and points to a spatial regulation within the epidermis. The reduced density of hemidesmosomes provides supporting evidence for plasticity at the epidermal-dermal junction. Altered hemidesmosome plasticity, and the sustained nature of LLP, may be mediated by the role of @entity6 in basal keratinocytes. The long-term sustained subtle changes detected are modest, but sufficient to create dramatic visual differences in skin colour. These results suggest that the @entity3 phenomenon leading to increased interdigitation develops in order to maintain normal skin homeostasis in individuals with LLP. Copyright    2014 Pathological Society of Great Britain and Ireland. Published by John Wiley _ Sons, Ltd.

title: UV exposure modulates hemidesmosome plasticity, contributing to long-term @entity4 in XXXX skin.

answer: @entity0


abstract: This study describes the expression characteristics of @entity7 molecules using immunogold histochemical techniques on cultured @entity0 umbilical vein endothelial cells (HUVEC). The expression of @entity7 was induced by @entity1 @entity2 factor-alpha ( @entity3 , 300 U/ml), @entity9 ( @entity8 , 10 ng/ml) and bacterial lipopolysaccharide (LPS, 4 micrograms/ml). No expression was demonstrated on control cells. Using the @entity4 -enhanced colloidal gold-labelling technique, at the light microscopical level, HUVEC could be distinctively subdivided into three staining types. The cell labelling index, expressed as the number of 'positively' stained cells as a proportion of all viewed cells was the highest in the LPS group. For @entity6 ( @entity6 ) the preembedding immunocytochemical staining method and embedding in @entity5 resin (Agar 100) according to standard procedures was used. In @entity6 gold particles were localized in close association with the apical plasma membrane, as well as on the surface of microvillus-like projections (the latter by @entity3 group). For high resolution scanning electron microscopy (HR-SEM) the secondary (SEI) and the backscattered electron imaging (BEI) modes were used. Gold particles were randomly distributed over the whole cell surface, although they appeared to be denser in the perinuclear zone. The quantitative evaluation on SE and BE viewing (the number of gold particles per cell area in microns 2) demonstrated the highest density of labelling in the LPS-treated group, but there was only a significant difference between LPS and @entity3 groups (P < 0.01, t-test). Furthermore, the ultrastructural studies indicated that treatment with substances which up-regulate @entity7 expression was not related to toxic cell damage or significant alterations of cellular ultrastructure.

title: Application of immunogold labelling for light and electron microscopic localization of XXXX ( @entity7 ) on cultured @entity0 endothelial cells.

answer: @entity7


abstract: This study describes the expression characteristics of @entity7 molecules using immunogold histochemical techniques on cultured @entity0 umbilical vein endothelial cells (HUVEC). The expression of @entity7 was induced by @entity1 @entity2 factor-alpha ( @entity3 , 300 U/ml), @entity9 ( @entity8 , 10 ng/ml) and bacterial lipopolysaccharide (LPS, 4 micrograms/ml). No expression was demonstrated on control cells. Using the @entity4 -enhanced colloidal gold-labelling technique, at the light microscopical level, HUVEC could be distinctively subdivided into three staining types. The cell labelling index, expressed as the number of 'positively' stained cells as a proportion of all viewed cells was the highest in the LPS group. For @entity6 ( @entity6 ) the preembedding immunocytochemical staining method and embedding in @entity5 resin (Agar 100) according to standard procedures was used. In @entity6 gold particles were localized in close association with the apical plasma membrane, as well as on the surface of microvillus-like projections (the latter by @entity3 group). For high resolution scanning electron microscopy (HR-SEM) the secondary (SEI) and the backscattered electron imaging (BEI) modes were used. Gold particles were randomly distributed over the whole cell surface, although they appeared to be denser in the perinuclear zone. The quantitative evaluation on SE and BE viewing (the number of gold particles per cell area in microns 2) demonstrated the highest density of labelling in the LPS-treated group, but there was only a significant difference between LPS and @entity3 groups (P < 0.01, t-test). Furthermore, the ultrastructural studies indicated that treatment with substances which up-regulate @entity7 expression was not related to toxic cell damage or significant alterations of cellular ultrastructure.

title: Application of immunogold labelling for light and electron microscopic localization of @entity7 ( XXXX ) on cultured @entity0 endothelial cells.

answer: @entity7


abstract: This study describes the expression characteristics of @entity7 molecules using immunogold histochemical techniques on cultured @entity0 umbilical vein endothelial cells (HUVEC). The expression of @entity7 was induced by @entity1 @entity2 factor-alpha ( @entity3 , 300 U/ml), @entity9 ( @entity8 , 10 ng/ml) and bacterial lipopolysaccharide (LPS, 4 micrograms/ml). No expression was demonstrated on control cells. Using the @entity4 -enhanced colloidal gold-labelling technique, at the light microscopical level, HUVEC could be distinctively subdivided into three staining types. The cell labelling index, expressed as the number of 'positively' stained cells as a proportion of all viewed cells was the highest in the LPS group. For @entity6 ( @entity6 ) the preembedding immunocytochemical staining method and embedding in @entity5 resin (Agar 100) according to standard procedures was used. In @entity6 gold particles were localized in close association with the apical plasma membrane, as well as on the surface of microvillus-like projections (the latter by @entity3 group). For high resolution scanning electron microscopy (HR-SEM) the secondary (SEI) and the backscattered electron imaging (BEI) modes were used. Gold particles were randomly distributed over the whole cell surface, although they appeared to be denser in the perinuclear zone. The quantitative evaluation on SE and BE viewing (the number of gold particles per cell area in microns 2) demonstrated the highest density of labelling in the LPS-treated group, but there was only a significant difference between LPS and @entity3 groups (P < 0.01, t-test). Furthermore, the ultrastructural studies indicated that treatment with substances which up-regulate @entity7 expression was not related to toxic cell damage or significant alterations of cellular ultrastructure.

title: Application of immunogold labelling for light and electron microscopic localization of @entity7 ( @entity7 ) on cultured XXXX endothelial cells.

answer: @entity0


abstract: OBJECTIVE: The aim of this study was to clarify how extracorporeal membrane oxygenation (ECMO) is used to treatcongenital @entity4 ( @entity6 ) in Japan. METHODS: We completed a nationwide survey of @entity6 involving 614 @entity0 . The subjects of this study included 43 @entity0 who underwent ECMO. We compared the clinical data ofthe @entity0 who did and did not survive for more than 90 days, and analyzed the 24-hour blood gas data in isolated @entity6 cases in both groups. RESULTS: Of the 43 @entity6 @entity0 , non-isolated @entity6 that was associated with other life-threatening or @entity3 was diagnosed in six @entity0 .Only one of these 6 @entity0 was able to discontinue ECMO and survived, and the other 5 died shortly after birth. The other 37 cases all had isolated @entity6 . The reason for initiating ECMO in 31 of these cases was persistent pulmonary @entity1 of the newborn (PPHN). In the 37 cases with isolated @entity6 , ECMO was initiated within 24 hours after birth. Sixteen @entity0 (37%) survived for more than 90 days, and intact discharge was possiblein eight cases. Among the isolated @entity6 @entity0 , the 90-day survival cutoff value based onthe ROC analysis @entity2 ( @entity5 )was 15. CONCLUSIONS: ECMO is used to treat PPHN starting from an early period after birth. However, the mortality and morbidity are not favorable. The index used to predict @entity0 who will survive following ECMO shows the lowest @entity5 of 15.

title: Extracorporeal membrane oxygenation for XXXX in Japan.

answer: @entity4


abstract: BACKGROUND: Non-specific @entity1 (NSLBP) is a large and costly problem. It has a lifetime prevalence of 80% and results in high levels of healthcare cost. It is a major cause for long term sickness amongst the workforce and is associated with high levels of fear avoidance and kinesiophobia. Stabilisation (or 'core stability') exercises have been suggested to reduce symptoms of @entity0 and disability and form an effective treatment. Despite it being the most commonly used form of physiotherapy treatment within the UK there is a lack of positive evidence to support its use. The aims of this systematic review update is to investigate the effectiveness of stabilisation exercises for the treatment of NSLBP, and compare any effectiveness to other forms of exercise. METHODS: A systematic review published in 2008 was updated with a search of PubMed, CINAHL, AMED, Pedro and The Cochrane Library, October 2006 to October 2013. Two authors independently selected studies, and two authors independently extracted the data. Methodological quality was evaluated using the PEDro scale. Meta-analysis was carried out when appropriate. RESULTS: 29 studies were included: 22 studies (n   =   2,258) provided post treatment effect on @entity0 and 24 studies (n   =   2,359) provided post treatment effect on disability. @entity0 and disability scores were transformed to a 0 to 100 scale. Meta-analysis showed significant benefit for stabilisation exercises versus any alternative treatment or control for long term @entity0 and disability with mean difference of -6.39 (95% CI -10.14 to -2.65) and -3.92 (95% CI -7.25 to -0.59) respectively. The difference between groups was clinically insignificant. When compared with alternative forms of exercise, there was no statistical or clinically significant difference. Mean difference for @entity0 was -3.06 (95% CI -6.74 to 0.63) and disability -1.89 (95% CI -5.10 to 1.33). CONCLUSION: There is strong evidence stabilisation exercises are not more effective than any other form of active exercise in the long term. The low levels of heterogeneity and large number of high methodological quality of available studies, at long term follow-up, strengthen our current findings, and further research is unlikely to considerably alter this conclusion.

title: An update of stabilisation exercises for XXXX : a systematic review with meta-analysis.

answer: @entity1


abstract: OBJECTIVES: To determine the efficacy and safety of the UroLume endoprosthesis as a treatment for obstructive @entity1 in healthy @entity0 . METHODS: One hundred twenty-six @entity0 were enrolled prospectively in a multicenter North American Clinical Trial. Ninety-five @entity0 (mean age 68 +/- 7 years) had moderate or severe prostatism, whereas 31 @entity0 (mean age 76 +/- 8 years) were in urinary retention. Voiding function for all @entity0 was assessed prior to stent placement and in follow-up at 1, 3, 6, 12, and 24 months with the Madsen-Iversen symptom questionnaire, peak urinary flow rate, postvoid residual urine volume, and cystoscopic examination. RESULTS: For the nonretention cohort at 24-month follow-up, the results were as follows: (1) total symptom score decreased from 14.3 +/- 0.5 preinsertion to 5.4 +/- 0.5 (p < 0.001); (2) peak urinary flow rate increased from 9.1 +/- 0.5 mL/s preinsertion to 13.1 +/- 0.7 mL/s (p < 0.001); and (3) postvoid residual urine volume decreased from 85 +/- 9 mL to 47 +/- 8 mL (p = 0.02). For the retention group, the total symptom score, peak urinary flow rate, and postvoid residual urine volume at 24 months were 4.1 +/- 0.5, 11.4 +/- 1.0 mL/s and 46 +/- 7 mL, respectively. By 12-month follow-up, most endoprostheses were completely covered with urothelium. Although significant long-term complications were minimal, 17 endoprostheses have been explanted for an overall removal rate of 13%. All devices were removed transurethrally without subsequent sequelae to the external urinary sphincter or urethra. CONCLUSIONS: The long-term results from this North American Clinical Trial suggest that the UroLume endoprosthesis can be an effective and safe treatment for properly selected healthy @entity0 with obstructive @entity1 . Randomized clinical trials comparing this minimally invasive procedure with transurethral resection of the prostate are now underway to document further its efficacy and safety.

title: The North American experience with the UroLume endoprosthesis as a treatment for XXXX : long-term results. The North American UroLume Study Group.

answer: @entity1


abstract: BACKGROUND: A prospective study was conducted to assess the efficacy and @entity2 of a salvage regimen consisting of CCNU, Melphalan, and @entity6 ( @entity8 ) given at 28-day intervals in @entity0 with @entity5 ( @entity5 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity0 AND METHODS: This study included 58 @entity0 (median age: 34 years), with resistant or relapsing @entity5 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity0 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity1 was present in 55% and B-symptoms in 72% of @entity0 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity8 was used as first salvage in half of the @entity0 . RESULTS: Complete remission was obtained in 17 @entity0 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity0 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity8 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity5 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity0 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity8 . The @entity8 @entity2 was mostly hematological; severe @entity7 occurred in six cases with two cases of @entity3 and one of fatal @entity4 . CONCLUSION: @entity8 therapy was moderately effective as third-line salvage in @entity0 with @entity5 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity2 was mostly hematological and supportive therapy was needed in one-third of the @entity0 .

title: Results of @entity8 regimen (CCNU, melphalan, and @entity6 ) as third-line salvage therapy for XXXX .

answer: @entity5


abstract: BACKGROUND: A prospective study was conducted to assess the efficacy and @entity2 of a salvage regimen consisting of CCNU, Melphalan, and @entity6 ( @entity8 ) given at 28-day intervals in @entity0 with @entity5 ( @entity5 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity0 AND METHODS: This study included 58 @entity0 (median age: 34 years), with resistant or relapsing @entity5 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity0 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity1 was present in 55% and B-symptoms in 72% of @entity0 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity8 was used as first salvage in half of the @entity0 . RESULTS: Complete remission was obtained in 17 @entity0 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity0 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity8 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity5 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity0 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity8 . The @entity8 @entity2 was mostly hematological; severe @entity7 occurred in six cases with two cases of @entity3 and one of fatal @entity4 . CONCLUSION: @entity8 therapy was moderately effective as third-line salvage in @entity0 with @entity5 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity2 was mostly hematological and supportive therapy was needed in one-third of the @entity0 .

title: Results of XXXX regimen (CCNU, melphalan, and @entity6 ) as third-line salvage therapy for @entity5 .

answer: @entity8


abstract: BACKGROUND: A prospective study was conducted to assess the efficacy and @entity2 of a salvage regimen consisting of CCNU, Melphalan, and @entity6 ( @entity8 ) given at 28-day intervals in @entity0 with @entity5 ( @entity5 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity0 AND METHODS: This study included 58 @entity0 (median age: 34 years), with resistant or relapsing @entity5 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity0 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity1 was present in 55% and B-symptoms in 72% of @entity0 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity8 was used as first salvage in half of the @entity0 . RESULTS: Complete remission was obtained in 17 @entity0 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity0 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity8 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity5 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity0 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity8 . The @entity8 @entity2 was mostly hematological; severe @entity7 occurred in six cases with two cases of @entity3 and one of fatal @entity4 . CONCLUSION: @entity8 therapy was moderately effective as third-line salvage in @entity0 with @entity5 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity2 was mostly hematological and supportive therapy was needed in one-third of the @entity0 .

title: Results of @entity8 regimen (CCNU, melphalan, and XXXX ) as third-line salvage therapy for @entity5 .

answer: @entity6


abstract: UNASSIGNED: Accurate force field parameters for ions are essential for meaningful simulation studies of proteins and nucleic acids. Currently accepted models of ions, especially for divalent ions, do not necessarily reproduce the right physiological behavior of @entity0 and @entity1 ions. Saxena and Sept (J. Chem. Theor. Comput. 2013, 9, 3538-3542) described a model, called the multisite-ion model, where instead of treating the ions as an isolated sphere, the charge was split into multiple sites with partial charge. This model provided accurate inner shell coordination of the ion with biomolecules and predicted better free energies for proteins and nucleic acids. Here, we expand and refine the multisite model to describe the behavior of divalent ions in concentrated @entity3 and @entity2 electrolyte solutions, eliminating the unusual ion-ion pairing and clustering of ions which occurred in the original model. We calibrate and improve the parameters of the multisite model by matching the osmotic pressure of concentrated solutions of @entity3 to the experimental values and then use these parameters to test the behavior of @entity2 solutions. We find that the concentrated solutions of both divalent ions exhibit the experimentally observed behavior with correct osmotic pressure, the presence of solvent separated ion pairs instead of direct ion pairs, and no aggregation of ions. The improved multisite model for ( @entity1 and @entity0 ) can be used in classical simulations of biomolecules at physiologically relevant salt concentrations.

title: Multisite Ion Model in Concentrated Solutions of Divalent Cations ( @entity3 and XXXX ): Osmotic Pressure Calculations.

answer: @entity2


abstract: UNASSIGNED: Accurate force field parameters for ions are essential for meaningful simulation studies of proteins and nucleic acids. Currently accepted models of ions, especially for divalent ions, do not necessarily reproduce the right physiological behavior of @entity0 and @entity1 ions. Saxena and Sept (J. Chem. Theor. Comput. 2013, 9, 3538-3542) described a model, called the multisite-ion model, where instead of treating the ions as an isolated sphere, the charge was split into multiple sites with partial charge. This model provided accurate inner shell coordination of the ion with biomolecules and predicted better free energies for proteins and nucleic acids. Here, we expand and refine the multisite model to describe the behavior of divalent ions in concentrated @entity3 and @entity2 electrolyte solutions, eliminating the unusual ion-ion pairing and clustering of ions which occurred in the original model. We calibrate and improve the parameters of the multisite model by matching the osmotic pressure of concentrated solutions of @entity3 to the experimental values and then use these parameters to test the behavior of @entity2 solutions. We find that the concentrated solutions of both divalent ions exhibit the experimentally observed behavior with correct osmotic pressure, the presence of solvent separated ion pairs instead of direct ion pairs, and no aggregation of ions. The improved multisite model for ( @entity1 and @entity0 ) can be used in classical simulations of biomolecules at physiologically relevant salt concentrations.

title: Multisite Ion Model in Concentrated Solutions of Divalent Cations ( XXXX and @entity2 ): Osmotic Pressure Calculations.

answer: @entity3


abstract: The anti-malarial agent @entity5 ( @entity4 ) has strong anti-angiogenic activity. This study aimed to investigate the molecular mechanism underlying this effect of @entity4 on angiogenesis. We found that @entity4 shows a dose-dependent inhibition of proliferation and migration of in HUVECs. @entity4 specifically down-regulates the mRNA and protein expression of @entity6 in endothelial cells. Treatment with @entity4 increases IkB-a protein and blocks nuclear translocation of NF-kB @entity2 . In addition, @entity4 directly regulates @entity6 promoter activity through @entity2 binding motif, and decreases the binding activity of @entity2 and @entity6 promoter, suggesting defective NF-kB signaling may underlie the observed effects of @entity4 on @entity6 expression. In the presence of the NF-kB inhibitor @entity7 , @entity4 could not further repress @entity6 . Co-treatment with @entity7 and @entity4 produced minimal changes compared to the effects of either drug alone in in vitro angiogenesis assays. Similar findings were found in vivo through a @entity1 @entity3 model examining the effects of @entity7 and @entity4 . Our data suggested that @entity4 inhibits angiogenesis largely through repression of the NF-kB pathway. @entity4 is well tolerated, and therefore may be an ideal candidate to use clinically as an angiogenesis inhibitor for @entity0 treatment.

title: @entity5 targets XXXX via the NF-kB pathway in endothelial cells to inhibit angiogenesis.

answer: @entity6


abstract: The anti-malarial agent @entity5 ( @entity4 ) has strong anti-angiogenic activity. This study aimed to investigate the molecular mechanism underlying this effect of @entity4 on angiogenesis. We found that @entity4 shows a dose-dependent inhibition of proliferation and migration of in HUVECs. @entity4 specifically down-regulates the mRNA and protein expression of @entity6 in endothelial cells. Treatment with @entity4 increases IkB-a protein and blocks nuclear translocation of NF-kB @entity2 . In addition, @entity4 directly regulates @entity6 promoter activity through @entity2 binding motif, and decreases the binding activity of @entity2 and @entity6 promoter, suggesting defective NF-kB signaling may underlie the observed effects of @entity4 on @entity6 expression. In the presence of the NF-kB inhibitor @entity7 , @entity4 could not further repress @entity6 . Co-treatment with @entity7 and @entity4 produced minimal changes compared to the effects of either drug alone in in vitro angiogenesis assays. Similar findings were found in vivo through a @entity1 @entity3 model examining the effects of @entity7 and @entity4 . Our data suggested that @entity4 inhibits angiogenesis largely through repression of the NF-kB pathway. @entity4 is well tolerated, and therefore may be an ideal candidate to use clinically as an angiogenesis inhibitor for @entity0 treatment.

title: XXXX targets @entity6 via the NF-kB pathway in endothelial cells to inhibit angiogenesis.

answer: @entity5


abstract: The complexation of Cm(iii) with the recombinant N-lobe of human serum @entity0 (hTf/2N) is investigated in the pH range from 4.0 to 11.0 using TRLFS. At pH >=  7.4 a Cm(iii) hTf/2N species is formed with Cm(iii) bound at the @entity2 binding site. The results are compared with Cm(iii) @entity0 interaction at the C-lobe and indicate the similarity of the coordination environment of the C- and N-terminal binding sites with four @entity1 residues of the protein, two @entity3 molecules and three additional ligands (e.g. synergistic anions such as @entity4 ) in the first coordination sphere. Measurements at c( @entity4 )tot = 0.23 mM (ambient @entity4 concentration) and c(carbonate)tot = 25 mM (physiological @entity4 concentration) show that an increase of the total @entity4 concentration suppresses the formation of the Cm(iii) hTf/2N species significantly. Additionally, the three Cm(iii) carbonate species Cm(CO3)(+), Cm(CO3)2(-) and Cm(CO3)3(3-) are formed successively with increasing pH. In general, @entity4 complexation is a competing reaction for both Cm(iii) complexation with @entity0 and hTf/2N but the effect is significantly higher for the half molecule. At c( @entity4 )tot = 0.23 mM the complexation of Cm(iii) with @entity0 and hTf/2N starts at pH >=  7.4. At physiological @entity4 concentration the Cm(iii) @entity0 species II forms at pH >=  7.0 whereas the Cm(iii) hTf/2N species is not formed until pH > 10.0. Hence, our results reveal significant differences in the complexation behavior of the C-terminal site of @entity0 and the recombinant N-lobe (hTf/2N) towards trivalent actinides.

title: Complexation of Cm(iii) with the recombinant N-lobe of human serum XXXX studied by time-resolved laser fluorescence spectroscopy (TRLFS).

answer: @entity0


abstract: The techniques introduced by Kimura and Ingram et al. were applied to assess the distribution of motor refractory periods (DMRPs) in peroneal nerve fibres of 28 diabetics with symptoms indicating @entity3 and in 28 controls. Results were compared with conventional motor nerve conduction velocity (MNCV) and compound muscle action potential (CMAP) measurements. MRP95 and MRP90 (the 5% and 10% slowest recovering fibres) obtained with Ingram's technique were prolonged in the @entity1 @entity0 . In the 26 @entity0 with a value of MRP95 and MNCV, a prolonged MRP95 and a decreased MNCV were found in 12 @entity0 . Thus conventional MNCV had a sensitivity of 46% to detect @entity2 ; addition of MRP95 obtained with Ingram's technique raised the sensitivity to 73%. Specificity was 100% in both cases. With Kimura's technique or with the fast recovering fibres in Ingram's technique, it was not possible to discriminate the @entity0 from the controls. This study indicates that measurement of the DMRP with the technique introduced by Ingram et al. improves the electrophysiological diagnosis of @entity4 .

title: Motor nerve refractory period distribution assessed by two techniques in XXXX .

answer: @entity4


abstract: UNASSIGNED: Although much is known about the neural mechanisms responsible for the mnemonic effects of 17b-estradiol (E2 ), very little is understood about the mechanisms through which @entity2 (P4 ) regulates memory. We previously showed that intrahippocampal infusion of P4 in ovariectomized female @entity0 enhances object recognition (OR) memory consolidation in a manner dependent on activation of dorsal hippocampal @entity6 and @entity3 signaling. However, the role of specific @entity2 receptors (PRs) in mediating the effects of @entity2 on memory consolidation and hippocampal cell signaling are unknown. Therefore, the goals of this study were to investigate the roles of membrane-associated and intracellular PRs in mediating hippocampal memory consolidation, and identify downstream cell signaling pathways activated by PRs. Membrane-associated PRs were targeted using bovine serum albumin-conjugated @entity2 (BSA-P), and intracellular PRs ( @entity8 , @entity1 ) were targeted using the intracellular PR agonist @entity7 . Immediately after OR training, ovariectomized @entity0 received bilateral dorsal hippocampal infusion of vehicle, P4 , BSA-P, or @entity7 . OR memory consolidation was enhanced by P4 , BSA-P, and @entity7 . However, only P4 and BSA-P activated @entity6 and @entity3 signaling. Furthermore, dorsal hippocampal infusion of the @entity6 inhibitor @entity5 blocked the memory-enhancing effects of BSA-P, but not @entity7 . The intracellular PR antagonist @entity4 blocked the memory-enhancing effects of @entity7 , but not BSA-P. Interestingly, P4 robustly activated canonical Wnt signaling in the dorsal hippocampus, which is consistent with our recent findings that canonical Wnt signaling is necessary for OR memory consolidation. @entity7 , but not BSA-P, also elicited a modest increase in canonical Wnt signaling. Collectively, these data suggest that activation of @entity6 signaling is necessary for membrane-associated PRs to enhance OR, and indicate a role for canonical Wnt signaling in the memory-enhancing effects of intracellular PRs. This study provides the first evidence that membrane and intracellular PRs may employ different molecular mechanisms to enhance hippocampal memory.    2014 Wiley Periodicals, Inc.

title: The XXXX and canonical Wnt signaling pathways mediate the mnemonic effects of @entity2 in the dorsal hippocampus.

answer: @entity3


abstract: UNASSIGNED: Although much is known about the neural mechanisms responsible for the mnemonic effects of 17b-estradiol (E2 ), very little is understood about the mechanisms through which @entity2 (P4 ) regulates memory. We previously showed that intrahippocampal infusion of P4 in ovariectomized female @entity0 enhances object recognition (OR) memory consolidation in a manner dependent on activation of dorsal hippocampal @entity6 and @entity3 signaling. However, the role of specific @entity2 receptors (PRs) in mediating the effects of @entity2 on memory consolidation and hippocampal cell signaling are unknown. Therefore, the goals of this study were to investigate the roles of membrane-associated and intracellular PRs in mediating hippocampal memory consolidation, and identify downstream cell signaling pathways activated by PRs. Membrane-associated PRs were targeted using bovine serum albumin-conjugated @entity2 (BSA-P), and intracellular PRs ( @entity8 , @entity1 ) were targeted using the intracellular PR agonist @entity7 . Immediately after OR training, ovariectomized @entity0 received bilateral dorsal hippocampal infusion of vehicle, P4 , BSA-P, or @entity7 . OR memory consolidation was enhanced by P4 , BSA-P, and @entity7 . However, only P4 and BSA-P activated @entity6 and @entity3 signaling. Furthermore, dorsal hippocampal infusion of the @entity6 inhibitor @entity5 blocked the memory-enhancing effects of BSA-P, but not @entity7 . The intracellular PR antagonist @entity4 blocked the memory-enhancing effects of @entity7 , but not BSA-P. Interestingly, P4 robustly activated canonical Wnt signaling in the dorsal hippocampus, which is consistent with our recent findings that canonical Wnt signaling is necessary for OR memory consolidation. @entity7 , but not BSA-P, also elicited a modest increase in canonical Wnt signaling. Collectively, these data suggest that activation of @entity6 signaling is necessary for membrane-associated PRs to enhance OR, and indicate a role for canonical Wnt signaling in the memory-enhancing effects of intracellular PRs. This study provides the first evidence that membrane and intracellular PRs may employ different molecular mechanisms to enhance hippocampal memory.    2014 Wiley Periodicals, Inc.

title: The @entity3 and canonical Wnt signaling pathways mediate the mnemonic effects of XXXX in the dorsal hippocampus.

answer: @entity2


abstract: @entity4 ( @entity4 ) is the fifth most common @entity0 . An important approach to control @entity4 is chemoprevention. This study aims at investigating the antitumor effect of @entity11 ( @entity10 ). @entity1 were injected with @entity2 ( @entity3 ) to establish @entity4 . Tumor development was observed. Liver function was evaluated. Apoptosis and cell cycle arrest-related makers and signaling cascades were determined by Western blot, RT-PCR and flow cytometric analysis. The administration of @entity10 could significantly inhibit @entity0 development in @entity3 -induced @entity4 @entity1 , shown by reduced incidence of @entity0 , decreased number of @entity0 nodules and reduced maximal size of @entity0 . @entity3 -induced increase of @entity9 aminotransferase, @entity8 aminotransferase, @entity5 dehydrogenase and alkaline phosphatase activities were significantly inhibited by @entity10 . @entity10 exhibited inhibitory effect on @entity4 through induction of apoptosis and cell cycle arrest in @entity1 . @entity10 induced apoptosis through increasing @entity7 , decreasing @entity6 , increasing the release of cytochrome c, and activating caspase, which consisted of the mitochondrial apoptotic pathway. @entity10 induced G2/M cell cycle arrest through down-regulation of @entity13 / @entity12 . In addition, inhibition of Akt and ERK signaling and the antioxidant activities of @entity10 may also contribute to its antitumor effect. These data provide new insight into the mechanisms underlying the antitumor effect of @entity10 .

title: INHIBITORY EFFECT OF XXXX ON HEPATOCELLULAR CARCINOMA: POSSIBLE ROLE OF APOPTOSIS AND CELL CYCLE ARREST.

answer: @entity11